On September 2nd, Propanc Biopharma announced its intention to purchase 100 million USD in Ethereum over the next year. This strategy aims to boost its cryptocurrency asset allocation and facilitate the development of new drugs.
The company selected Ethereum due to its support for smart contracts and decentralized applications, coupled with advantages in liquidity and energy efficiency compared to Bitcoin. Part of the funds will also be used for intellectual property acquisition.
Leave a Reply